CDI Detection via Metabolite Profiling and Nucleic Acid Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Clostridioides difficile infection (CDI) often misdiagnose cases due to inability to differentiate colonization from symptomatic disease, leading to inadequate treatment decisions.
Innovation Solution
A method involving the measurement of specific analyte signatures in biological samples, such as fecal samples, using mass spectrometry to identify CDI by determining the levels of short chain fatty acids, amino acids, bile acids, carbohydrates, and lipids, which helps in accurately diagnosing and treating CDI.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If nucleic acid amplification tests are used for CDI diagnosis, then test speed and cost effectiveness are improved, but diagnostic accuracy deteriorates due to inability to differentiate colonization from symptomatic disease
Solution Approach 1:
The diagnostic approach is segmented into two distinct components: (1) nucleic acid amplification to detect C. difficile presence, and (2) metabolite profile analysis to distinguish colonization from symptomatic disease. This segmentation allows each component to perform its specialized function, resolving the contradiction between speed and accuracy.
Solution Approach 2:
Metabolite profiles serve as an intermediary marker that bridges the gap between detecting bacterial presence and determining disease state. The metabolite signature acts as a mediator that translates the presence of bacteria into clinically meaningful diagnostic information, enabling accurate differentiation without sacrificing test speed.
2Ease of manufacture
If nucleic acid amplification tests are used for CDI diagnosis, then cost effectiveness is improved, but diagnostic reliability deteriorates due to misdiagnosis rates
Solution Approach 1:
The diagnostic system is divided into a primary screening component (nucleic acid amplification) and a confirmatory component (metabolite profiling). This segmentation allows cost-effective initial screening while ensuring reliable final diagnosis through the added metabolite analysis layer.
Solution Approach 2:
The diagnostic approach changes from detecting a single parameter (bacterial DNA presence) to analyzing multiple parameters (metabolite concentrations and ratios). This multi-parameter approach significantly improves diagnostic reliability while maintaining cost effectiveness through targeted metabolite measurement.
3Measurement precision
If metabolite profiling is added to CDI detection, then diagnostic accuracy is improved, but test complexity increases
Solution Approach 1:
The metabolite profiling system is designed to simultaneously measure multiple metabolites and calculate various ratios from a single sample analysis. This multi-functionality allows comprehensive diagnostic information to be obtained without proportionally increasing procedural complexity, as the same analytical platform performs multiple measurements.
4Reliability
If multiple analytes are measured for CDI detection, then diagnostic robustness is improved, but measurement complexity increases
Solution Approach 1:
The measurement of multiple analytes is merged into a single integrated metabolite profiling assay. Rather than performing separate measurements for each metabolite, the system combines them into one coordinated analysis, measuring all relevant metabolites and calculating ratios simultaneously from the same sample preparation and analysis run.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a robust CDI detection assay, improving diagnostic accuracy and guiding treatment decisions by distinguishing between active CDI and colonization, thereby enhancing patient management.
Implementation Method 1
the analyte levels are measured by mass spectrometry
Data Source
AI summary
The present disclosure provides methods related to accurate detection and treatment of medical conditions related to Clostridioides difficile infection (CDI). In specific cases, the disclosure concerns accurate assessment of a symptom associated with CDI related to the presence or risk that may or may not be a pathogenic infection. Particular embodiments encompass detection of one or more specific analytes that provide information for accurate diagnosis and treatment of CDI.